TORRENT PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,883 INR | +0.33% |
|
+1.40% | +25.06% |
| Sales 2024 | 11TCr 128.44Cr | Sales 2025 * | 12TCr 144.81Cr | Capitalization | 98TCr 1.17TCr |
|---|---|---|---|---|---|
| Net income 2024 | 1.66TCr 20Cr | Net income 2025 * | 2.04TCr 24Cr | EV / Sales 2024 | 8.21 x |
| Net Debt 2024 * | 3.68TCr 44Cr | Net Debt 2025 * | 2.15TCr 26Cr | EV / Sales 2025 * | 8.24 x |
| P/E ratio 2024 |
53.1
x | P/E ratio 2025 * |
47.8
x | Employees | 13,247 |
| Yield 2024 * |
0.75% | Yield 2025 * |
0.87% | Free-Float | 28.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Torrent Pharmaceuticals Limited
More recommendations
More press releases
| 1 day | +0.33% | ||
| 1 week | +1.40% | ||
| Current month | +6.90% | ||
| 1 month | +8.75% | ||
| 3 months | +11.37% | ||
| 6 months | +37.70% | ||
| Current year | +25.06% |
1 week
2 800.05
2 919.95
1 month
2 576.402 919.95
Current year
2 270.152 919.95
1 year
1 771.352 919.95
3 years
1 242.502 919.95
5 years
726.502 919.95
10 years
327.752 919.95
| Managers | Title | Age | Since |
|---|---|---|---|
Sudhir Menon
DFI | Director of Finance/CFO | - | - |
| Compliance Officer | - | 01/22/01 | |
Jinesh Shah
COO | Chief Operating Officer | 47 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 23/82/23 | |
| Chairman | 60 | 01/86/01 | |
Nayantara Bali
BRD | Director/Board Member | 57 | 07/19/07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.28% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 2,883 | +0.33% | 1,244 |
| 13/24/13 | 2,873 | -0.73% | 6,096 |
| 12/24/12 | 2,894 | +1.54% | 3,609 |
| 11/24/11 | 2,851 | -0.47% | 7,859 |
| 10/24/10 | 2,864 | +0.75% | 3,016 |
Delayed Quote Bombay S.E., June 14, 2024 at 03:30 pm IST
More quotes
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Sector
Pharmaceuticals
Calendar
21/06/2024
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
2,883
INR
Average target price
2,850
INR
Spread / Average Target
-1.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.06% | 1.17TCr | |
| +50.70% | 79TCr | |
| +41.96% | 63TCr | |
| -7.15% | 35TCr | |
| +18.77% | 33TCr | |
| +8.79% | 30TCr | |
| +18.02% | 25TCr | |
| +1.27% | 22TCr | |
| +11.95% | 22TCr | |
| +3.68% | 16TCr |
- Stock Market
- Equities
- TORNTPHARM Stock
